Published in Chem Rev on July 13, 2015
Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. J Control Release (2016) 0.82
Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines. ACS Nano (2016) 0.79
3D Imaging of Nanoparticle Distribution in Biological Tissue by Laser-Induced Breakdown Spectroscopy. Sci Rep (2016) 0.77
Pillar[5]arene-based amphiphilic supramolecular brush copolymer: fabrication, controllable self-assembly and application in self-imaging targeted drug delivery. Polym Chem (2016) 0.75
Multimodality imaging in nanomedicine and nanotheranostics. Cancer Biol Med (2016) 0.75
Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res (2016) 0.75
Advances in Magnetic Resonance Imaging Contrast Agents for Biomarker Detection. Annu Rev Anal Chem (Palo Alto Calif) (2016) 0.75
Physico-Chemical Strategies to Enhance Stability and Drug Retention of Polymeric Micelles for Tumor-Targeted Drug Delivery. Macromol Biosci (2016) 0.75
The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds. Sci Rep (2017) 0.75
Tumor microenvironment-triggered fabrication of gold nanomachines for tumor-specific photoacoustic imaging and photothermal therapy. Chem Sci (2017) 0.75
Recent development of nanoparticles for molecular imaging. Philos Trans A Math Phys Eng Sci (2017) 0.75
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev (1999) 12.52
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol (2003) 10.76
Drug delivery systems: entering the mainstream. Science (2004) 9.27
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 7.79
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol (2008) 6.41
Drug delivery and targeting. Nature (1998) 6.16
Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol (2002) 6.06
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng (2007) 5.82
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer (2006) 5.75
Going deeper than microscopy: the optical imaging frontier in biology. Nat Methods (2010) 5.65
Fluorescence molecular tomography resolves protease activity in vivo. Nat Med (2002) 5.53
In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 4.94
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med (2008) 4.54
Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev (2001) 4.52
Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett (2005) 3.96
Fluorescence molecular imaging. Annu Rev Biomed Eng (2006) 3.70
Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation (2003) 3.68
Carbon Nanotubes in Biology and Medicine: In vitro and in vivo Detection, Imaging and Drug Delivery. Nano Res (2009) 3.63
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Noninvasive imaging of hemoglobin concentration and oxygenation in the rat brain using high-resolution photoacoustic tomography. J Biomed Opt (2006) 3.52
Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents. Nat Nanotechnol (2009) 3.50
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res (2001) 3.48
Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation. Opt Lett (2001) 3.43
Photoacoustic tomography of a rat cerebral cortex in vivo with au nanocages as an optical contrast agent. Nano Lett (2007) 3.42
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation (2003) 3.15
Three-dimensional photoacoustic imaging of blood vessels in tissue. Opt Lett (1998) 3.12
Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation (2001) 3.12
Photoacoustic imaging and characterization of the microvasculature. J Biomed Opt (2010) 3.07
Gold nanocages: synthesis, properties, and applications. Acc Chem Res (2008) 3.03
Multiwavelength photoacoustic imaging and plasmon resonance coupling of gold nanoparticles for selective detection of cancer. Nano Lett (2009) 2.91
Nanoparticle-based theranostic agents. Adv Drug Deliv Rev (2010) 2.86
Near-infrared gold nanocages as a new class of tracers for photoacoustic sentinel lymph node mapping on a rat model. Nano Lett (2009) 2.82
Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev (2008) 2.80
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst (2007) 2.77
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Multimodality imaging probes: design and challenges. Chem Rev (2010) 2.61
A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med Phys (2003) 2.58
MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol (2005) 2.57
Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed (2006) 2.57
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release (2011) 2.37
Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev (2010) 2.37
Sentinel lymph nodes in the rat: noninvasive photoacoustic and US imaging with a clinical US system. Radiology (2010) 2.35
18F-fluorodeoxyglucose positron emission tomography/computed tomography enables the detection of recurrent same-site deep vein thrombosis by illuminating recently formed, neutrophil-rich thrombus. Circulation (2014) 2.30
Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation (1998) 2.30
In vivo molecular photoacoustic tomography of melanomas targeted by bioconjugated gold nanocages. ACS Nano (2010) 2.29
Silica-coated gold nanorods as photoacoustic signal nanoamplifiers. Nano Lett (2011) 2.28
Molecular imaging by means of multispectral optoacoustic tomography (MSOT). Chem Rev (2010) 2.27
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging (2009) 2.17
Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci U S A (2010) 2.17
Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol (2009) 2.15
Optical image-guided surgery--where do we stand? Mol Imaging Biol (2011) 2.15
In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small (2008) 2.09
Nanomedicine(s) under the microscope. Mol Pharm (2011) 2.09
Induction of cell-membrane porosity by ultrasound. Lancet (1999) 2.06
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst (2007) 2.03
Plasmonic intravascular photoacoustic imaging for detection of macrophages in atherosclerotic plaques. Nano Lett (2009) 1.99
Theranostic nanomedicine for cancer. Nanomedicine (Lond) (2008) 1.96
Theranostic nanomedicine. Acc Chem Res (2011) 1.84
Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance. Trends Biotechnol (2011) 1.84
18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem (2009) 1.78
Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound Med Biol (2006) 1.75
Challenges for molecular magnetic resonance imaging. Chem Rev (2010) 1.67
Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer (2007) 1.65
High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors. ChemMedChem (2011) 1.63
Diagnostic ultrasound activation of contrast agent gas bodies induces capillary rupture in mice. Proc Natl Acad Sci U S A (2000) 1.63
Hybrid system for simultaneous fluorescence and x-ray computed tomography. IEEE Trans Med Imaging (2009) 1.62
Long-circulating liposomes radiolabeled with [18F]fluorodipalmitin ([18F]FDP). Nucl Med Biol (2007) 1.60
Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc Natl Acad Sci U S A (2006) 1.57
(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med (2005) 1.56
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med (2003) 1.56
Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol (2008) 1.55
Molecular imaging applications in nanomedicine. Biomed Microdevices (2004) 1.54
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol (2002) 1.52
Investigations into pulsed high-intensity focused ultrasound-enhanced delivery: preliminary evidence for a novel mechanism. Ultrasound Med Biol (2009) 1.51
Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined (64)Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers. Biomacromolecules (2007) 1.51
Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res (2009) 1.49
Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew Chem Int Ed Engl (2011) 1.47
FMT-XCT: in vivo animal studies with hybrid fluorescence molecular tomography-X-ray computed tomography. Nat Methods (2012) 1.44
PET imaging in oncology. Semin Nucl Med (2000) 1.42
Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res (2009) 1.42
Molecular imaging with theranostic nanoparticles. Acc Chem Res (2011) 1.41
Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med (2012) 1.38
In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med (2011) 1.38
Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett (2014) 1.37
Optical imaging in drug discovery and diagnostic applications. Adv Drug Deliv Rev (2005) 1.33
Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study. J Control Release (2010) 1.32
Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm (2008) 1.30
Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release (2005) 1.30
High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.30
Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond) (2007) 1.28